SecBot SecBot
8-K ·Filed Aug 10, 2026

NKTX

Nkarta, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-342402
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The widening net loss and accelerating cash burn without any clinical data catalyst are negative for the stock. The $0.54 EPS miss vs $0.36 consensus is a significant disappointment for a pre-revenue biotech. Monitor for the first clinical data readout from Ntrust-1 and Ntrust-2, expected at a medical conference in 2026, as the next potential catalyst.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.33
T+0 close · Aug 10, 2026 · via day close
Latest settled
−25.75%
T+60 · $1.73
Vs SPY
−25.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $2.33entry
  2. T+1 · 3mo ago +2.58%α +2.32% · $2.39
  3. T+5 · 3mo ago +3.43%α +3.84% · $2.41
  4. T+20 · 2mo ago +24.89%α +25.95% · $2.91
  5. T+60 · 13d ago −25.75%α −25.26% · $1.73
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of -$0.36 per share. The net loss widened to $40.4 million from $23.0 million a year ago, driven by a 59% increase in operating expenses, including an $8.0 million impairment charge. Cash burn accelerated, with cash and investments declining to $243.2 million from $295.1 million at year-end 2025, though the company maintains a cash runway into 2029. No clinical data catalysts were announced, with initial data still expected at a medical conference in 2026.

Key Financial Metrics

EPS
−$0.54
est −$0.36 · -50.0%
Rating
miss

Key Facts

  • Net loss per share was -$0.54 vs consensus -$0.36, a 48.6% miss.
  • Net loss widened to $40.4M in Q2 2026 from $23.0M in Q2 2025.
  • Operating expenses surged 59% YoY to $43.1M, including an $8.0M impairment charge.
  • Cash and investments fell to $243.2M from $295.1M at Dec 31, 2025, a $51.9M decline in six months.
  • Cash runway guidance unchanged, expected to fund operations into 2029.
  • No clinical data update; initial Ntrust-1 and Ntrust-2 data still planned for a medical conference in 2026.

Financial Impact

Net loss per share of -$0.54 missed consensus of -$0.36 by $0.18 per share. Net loss increased $17.4M YoY to $40.4M.

epsnetLosscashBurnoperatingExpenses

Risk Factors

  • No approved products or revenue; continued operating losses.
  • Cash burn accelerated to ~$26M/quarter in H1 2026 from ~$18M/quarter in H1 2025.
  • Clinical-stage risk, NKX019 may fail to demonstrate efficacy or safety in ongoing trials.
  • Potential need for future dilutive financing if cash runway shortens.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-342402
Document: nktx-20260810.htm0001193125-26-342402
Document: 0001193125-26-342402-index-headers.html0001193125-26-342402
Document: 0001193125-26-342402-index.html0001193125-26-342402
Document: 0001193125-26-342402.txt0001193125-26-342402
8-K Data (Synthetic)0001193125-26-342402

Track record

13 reports on NKTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  2. Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
  6. Aug 10, 202614w ago 8-K Bearish 6/10 Viewing Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
  7. May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
  8. Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
  9. Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
  10. Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026